Related Experiment Video
Updated: May 30, 2025
07:37
Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
23.5K
Short-Term Evolution of MASLD Following Roux-en-Y Gastric Bypass: A Focus on Fibrotic MASH.
Christian Bornia Matavelli1, Luisa Souza Echeverria1, Luca Maunsell Pereira1
1State University of Campinas, Campinas, Brazil.
Obesity Surgery
|January 27, 2025
Summary
Roux-en-Y gastric bypass (RYGB) significantly improves fibrotic metabolic dysfunction-associated steatohepatitis (MASH), as measured by the fibrotic NASH index (FNI). This weight loss surgery shows promise for mitigating MASLD progression and offers effective assessment tools.
Area of Science:
- Bariatric Surgery
- Hepatology
- Metabolic Disorders
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses simple steatosis and MASH.
- Fibrosis in MASH is a key prognostic indicator.
- Investigating interventions for fibrotic MASH is crucial for patient outcomes.
Purpose of the Study:
- To evaluate the impact of Roux-en-Y gastric bypass (RYGB) on fibrotic MASH.
- To assess the diagnostic accuracy of the fibrotic NASH index (FNI) and non-invasive NASH detection score (NI-NASH-DS).
Main Methods:
- Retrospective cohort study of 104 patients undergoing RYGB.
- Histopathological evaluation for fibrotic MASH.
- Calculation of FNI and NI-NASH-DS at baseline and 1-year post-surgery.
Main Results:
- RYGB led to significant reduction in FNI scores (p < 0.0001).
- Female gender and lobular inflammation were linked to FNI improvement.
- FNI showed high diagnostic accuracy (90.2%), with 96.4% specificity.
Conclusions:
- RYGB demonstrates potential as a therapeutic strategy for improving fibrotic MASH.
- FNI and NI-NASH-DS are valuable, cost-effective tools for MASH assessment.
